Clinical trials: Patients With Major Depressive Disorder
Major Depression Moderate, Major Depression Severe
EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07748091
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy of SSR149415 in the treatment of Major Depressive Disorder, defined as a change from baseline to visit 7 in the Hamilton Depression Rating Scale.
- Trial name
- LENA (NCT00361491)
- Testing
- SSR149415
- Where
- 7 sites in Argentina, Bulgaria and 5 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Depressive Disorder, Major, Self-Injurious Behavior
Transcranial Magnetic Stimulation in Patients With Depression and Non-suicidal Self-injury
This clinical trial aims to investigate the effects of Transcranial Magnetic Stimulation (TMS) as an adjunctive treatment for young adult patients with depression and non-suicidal self-injury (NSSI).
- Trial name
- NCT06110585
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Brain Institute of Rio Grande do Sul
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969150
- Testing
- Levomilnacipran ER
- Where
- 25 sites in United States
- Volunteers
- 362 people
- Sponsor
- Forest Laboratories
Posttraumatic Stress Disorder (PTSD), Depression - Major Depressive Disorder
To Investigate the Change of Brain and Autonomic Function From Different Protocols of Repeated Transcranial Magnetic Stimulation Therapy for Patients With Post-traumatic Stress Disorder Comorbid Major Depressive Disorder
This study aims to investigate the immediate neurophysiological and autonomic effects of two noninvasive brain stimulation protocols-prolonged intermittent theta-burst stimulation (prolonged iTBS) and high-frequency repetitive…
- Trial name
- NCT07327385
- Testing
- Prolonged Intermittent Theta-Burst Stimulation (prolonged iTBS), High-Frequency Repetitive Transcranial Magnetic Stimulation (HF-rTMS)
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Bipolar Depression
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major…
- Trial name
- NCT03249376
- Testing
- Lumateperone
- Where
- 47 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
Background. Depression is a highly frequent condition in the elderly, with a huge impact on quality of life, life expectancy, and medical outcomes.
- Trial name
- VESPA (NCT03779789)
- Testing
- Vortioxetine, Sertraline, citalopram
- Where
- 3 sites in Italy
- Volunteers
- 362 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Treatment Resistant Depression, Suicidal Ideation
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation
- Trial name
- NCT05220410
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sheppard Pratt Health System
Depression, Depressive Disorder
Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) for Depression
Feeling sad about negative or stressful events has nothing to do with the diagnosis of depression, as this is a very prevalent mental illness among the population with devastating consequences for the person suffering from it.
- Trial name
- INCREM (NCT06590025)
- Testing
- INtegral Cognitive REMediation program, Psychoeducation for depression
- Where
- Spain
- Volunteers
- 296 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Major Depressive Disorder
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
This study was a single-arm, open-label clinical study to assess dopamine transporter occupancy in the brain of patients with depression using 11C-CFT positron emission tomography (PET).
- Trial name
- NCT06026917
- Testing
- Toludesvenlafaxine hydrochloride sustained-release tablets
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder
The primary object of this study is to confirm the superiority of tianeptine compared to escitalopram on effects that improves subjective and objective cognitive impairments in patients suffering from major depressive disorder.
- Trial name
- CAMPION (NCT01309776)
- Testing
- Tianeptine, Escitalopram
- Where
- 6 sites in South Korea
- Volunteers
- 164 people
- Sponsor
- Samsung Medical Center
Bipolar Disorder；Major Depressive Disorder；Mood Disorders
Investigation on Risk Factors for Suicide Among Chinese Patients With Mood Disorders
Main research objective: Through questionnaire surveys, obtain the occurrence levels of self-harm/suicide behaviors, the status of acquired suicidal ability, and their correlations with self-harm/suicide behaviors among patients…
- Trial name
- NCT07281729
- Where
- 2 sites in China
- Volunteers
- 25,000 people
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics
Depressive Disorder, Major Depressive Disorder
Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder
This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks.
- Conditions
- Depressive Disorder, Major Depressive Disorder, Depressive Episode
- Trial name
- NCT05701345
- Testing
- OMNIFIT DTx-MDD, standard treatment
- Where
- 5 sites in South Korea
- Volunteers
- 162 people
- Sponsor
- Omni C&S
Major Depressive Disorder, Anxiety Disorders
Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients
The objective of this transversal study is to determine if there is a difference in the volume of the hippocampus with the degree of anxiety.
- Trial name
- NCT04430556
- Testing
- Sertraline
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Depressive Disorder
Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder
The purpose of this study is to validate the effectiveness of using an integrated mobile sensing platform to deliver large-scale data-driven interventions to patients with depression.
- Trial name
- NCT02499094
- Testing
- Behavioral-data driven support
- Volunteers
- 1,004 people
- Sponsor
- Ginger.io
Major Depressive Disorder
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major depressive disorder patients with lack of response to existing antidepressants, with the aim of evaluating the efficacy of quetiapine XR and…
- Trial name
- NCT01725282
- Testing
- quetiapine extended release (XR)
- Where
- 3 sites in Japan
- Volunteers
- 172 people
- Sponsor
- Astellas Pharma Inc
Major Depression
Functional Neuroimaging in Depression
Oral administration of escitalopram during 8 weeks; PET scan with 18F-FDG at inclusion and after 8 weeks
- Trial name
- NCT00343070
- Testing
- Oral administration of escitalopram during 8 weeks
- Where
- 2 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent